

**The Prostate Cancer Foundation (PCF) and Pfizer Inc.**  
**Independent Medical Education**  
**Implementing Germline and Somatic Testing**  
**for Precision Medicine in Community-Based**  
**Prostate Cancer Care**  
**Visiting Professorship Program**  
**Request for Proposals (RFP)**

**I. Background**

**About the Prostate Cancer Foundation**

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has raised more than \$1 billion to fund cutting-edge research through more than 2,615 research projects at 312 leading cancer centers, with a global footprint spanning 29 countries. Since PCF's inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to the mission of ending death and suffering from this disease. Learn more at [pcf.org](http://pcf.org).

**About Pfizer Global Medical Grants**

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. Pfizer's GMG competitive grant program involves a publicly posted **RFP** that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses a scientific review committee (SRC) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in practice or care as outlined in the specific RFP.

**About this Visiting Professorship (VP) Program**

This RFP is to provide financial support to community-based urology and medical oncology Organizations (e.g., independent community urology practices governed by a Board of Directors, community-based medical oncology groups, hospital-affiliated community cancer centers) to host and coordinate a 2.5-to-3 hour medical education program to be led by 1-2 Visiting Professors whose expertise matches the Organization's unmet educational and practice needs related to germline/genetic and somatic (tumor and/or ctDNA) testing for patients with prostate cancer, such as:

- Understanding the science of these tests and clinical applications of testing
- Patient selection (whom to test and when)
- Communicating benefits of testing, risks and results and implications to patients and families
- Effective strategies to integrate testing into clinical workflows, such as enabling advanced practice providers to provide support and/or incorporating novel digital tools that support clinical decision-making
- Addressing and overcoming financial and reimbursement barriers to testing



Targeting these gaps, the goals of this first-time competitive Visiting Professor program are to provide meaningful education for prostate cancer care teams in community practice, building capacity by helping them identify gaps in patient care, helping engineer practice-level solutions, and fostering collaborations among community-based practitioners and academic experts. Urologists, medical oncologists, advanced practice providers, and patients will benefit from the knowledge and onsite presence of distinguished clinical experts who might otherwise be inaccessible.

The goal of this program is to help initiate/ implement a practice level-solution to improve the delivery of prostate cancer care at the grantee’s site specific to their unique practice gaps related to germline and somatic testing. Our support for this program reflects our commitment to improving outcomes for patients with prostate cancer and advancing clinical expertise, education, and capacity for healthcare professionals.

**II. Eligibility**

|                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Geographic Scope:</b>                  | United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Institutions Eligibility Criteria:</b> | <ul style="list-style-type: none"> <li>• Applicant must have a medical degree (MD, DO, MBBS, NP or equivalent) and hold a position as a urologist or medical oncologist seeing patients with prostate cancer.</li> <li>• Applicant must be an employee or independent contractor of the requesting Organization.</li> <li>• The requesting Organization must be a urology and/or medical oncology Organization providing care for patients with prostate cancer.</li> <li>• Applicant should serve as Chair of the proposed medical education program and play a lead role in implementation.</li> <li>• Only community-based urology or medical oncology practices (Organizations) are eligible to receive Grants.</li> <li>• Organization and hosting team must be in the United States.</li> <li>• The education program may involve participants from multiple clinical specialties or service areas within the Organization as long as all participants have a relevant role and educational need.</li> <li>• Organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this prior to applying. Grants approved to organizations that are subsequently determined to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.</li> </ul> |

**III. Requirements**

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Date RFP Issued:</b>               | <b>April 22, 2026</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Clinical Area:</b>                 | <b>Urology and Oncology – Genitourinary – Prostate Cancer</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Area of Interest for this RFP:</b> | <p>The intent of this Request for Proposal (RFP) is to invite organizations to submit applications to host a 2.5-to-3 hour medical education program at or nearby the organization, to be led by 1-2 Visiting Professors (VPs) with expertise matched to the organization’s unmet educational and pragmatic needs related to integrating and acting on germline and somatic (tumor and/or ctDNA) testing for patients with prostate cancer. Following the education program, organizations will implement projects to incorporate, increase, or improve the use of guideline-concordant germline and somatic testing to improve prostate cancer patient care.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Application Requirements:</b>      | <p><b>Applications from organizations interested in hosting this program must include, but are not limited to, the following:</b></p> <ul style="list-style-type: none"> <li>● <b>Description of the Organization’s mission, vision, impact, and reach.</b> This includes statistics and descriptions of the following:           <ul style="list-style-type: none"> <li>● Mission and Vision of Organization.</li> <li>● Organization’s structure and geographic area served.</li> <li>● Prostate cancer prevention, screening, diagnosis, and treatment services, certifications, and specialties offered.</li> <li>● Number of prostate cancer patients served and number of visits.</li> <li>● Estimated current testing rates for somatic and germline testing.</li> <li>● Any underserved or high-risk patient populations seen.</li> <li>● Total and individual numbers of clinical staff providing prostate cancer care i.e. urologists, medical oncologists, APPs, nurses, navigators, genetic counselors, etc.</li> <li>● Any involvement in clinical trials.</li> <li>● Any prostate cancer educational platforms or programs.</li> </ul> </li> <li>● <b>Description of the organization’s medical gaps, unmet needs, challenges, and questions surrounding providing and utilizing germline and somatic testing for the management of patients with prostate cancer, for which a Visiting Professor could provide education, such as:</b> <ul style="list-style-type: none"> <li>● Training needs of healthcare team, including physicians, nurses, and other allied health professionals.               <ul style="list-style-type: none"> <li>▪ May include but is not limited to the following: core concepts and clinical applications for testing, patient</li> </ul> </li> </ul> </li> </ul> |

selection, use of results for prognostication, management / treatment selection, clinical trial referrals, communicating about tests and results with patients and families.

- Gaps or challenges related to integrating tests into clinical workflows, any solutions attempted to date, impact and any planned improvements.
  - Prostate cancer care disparities that program can impact.
  - Support needs related to addressing costs of these tests, insurance/payers, etc.
- **Draft agenda for a 2.5-to-3-hour medical education program covering a concise clinical review, discussion of practice-specific gaps, and solutions to address these gaps.** Agenda should include but is not limited to:
    - Description of desired expertise from Visiting Professor(s) and desired medical discipline.
    - Proposed (example) agenda for topics to be covered. The VP and awardee can work together to further elaborate on the agenda once the VP is assigned to the site.
    - Documents (if any) for review, including but not limited to: workflows, processes, staffing
    - Expected number of healthcare professionals attending this Program.
    - Proposed site (program will include didactic and discussion components and includes a meal – breakfast, lunch, or dinner. PCF will work with awardees on location which could be onsite or offsite/nearby for participants.
  - **Line-item budget for all local costs for project implementation at healthcare site** such as local onsite management, logistics, staff time, planning, and other implementation or initiation costs. **PCF will cover all medical education meeting expenses**, including room rental if required, meal, and AV, as well as travel expenses and honoraria for Visiting Professors; therefore, **these costs should not be included in the budget.** The total budget for the RFP is \$250,000 USD, with plans to support 5-7 organizations.
  - **Describe how the Visiting Professorship Program is expected to improve the Organization's prostate cancer patient care and healthcare provider education / knowledge. Please include at least 2 quantifiable outcome metrics related to the project goal, to be discussed and confirmed during the education program and included in a concise outcomes report submitted by the Organization 6 and 12 months after the program (e.g. a baseline**



|                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                          | <p><b>to current practice post-activity comparison).</b></p> <p>These outcome reports may also include but are not limited to:</p> <ul style="list-style-type: none"> <li>• Changes in patient management and outcomes</li> <li>• Impact on healthcare provider knowledge and/or patient understanding related to unmet needs</li> <li>• Resulting practice changes, and the sustainability of those changes</li> <li>• Potential replicability</li> <li>• Collaborations with or dissemination to other oncology sites, medical groups, etc.</li> </ul> <ul style="list-style-type: none"> <li>• <b>Availability / interest in participating in PCF Scientific Retreat.</b><br/>In 2027, PCF will provide registration and travel support for one participant per Organization to attend the PCF Scientific Retreat, the world’s foremost scientific conference on prostate cancer biology and treatment, which is held annually in autumn. Please indicate Organization’s interest and expected availability to attend.</li> <li>• <b>Availability and willingness to participate in video interviews.</b><br/>After the program, PCF will create videos in which participants describe their Organization’s baseline somatic and germline genetic testing challenges, learnings, practice-specific solutions, and concrete outcomes. These videos help disseminate key learnings to a wider clinical audience and will be hosted publicly on UroToday. Please indicate your interest and willingness to participate in a video interview, either onsite at PCF Scientific Retreat or virtually.</li> </ul> |
| <p><b>Target Audience:</b></p>                                           | <p>Urologist or medical oncologist should serve as Program Chair, but all other medical disciplines can be included in the Program plan, such as pathologists, APPs, nurses, navigators, other allied prostate cancer healthcare providers, genetic counselors, etc.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <p><b>Expected Approximate Monetary Range of Grant Applications:</b></p> | <ul style="list-style-type: none"> <li>• The total budget for the RFP is \$250,000 USD, with plans to support 5-7 organizations. Individual project budgets should not exceed \$50,000 USD.</li> <li>• <b>Please note:</b> PCF will select 1-2 Visiting Professors based on the approved program and its knowledge gaps. Offsite or onsite physical meeting expenses including room, meals and AV as well as <b>travel expenses and honoraria for Visiting Professors</b>, will be covered separately and are not part of this Grant budget.</li> <li>• Approximately <b>five to seven sites (5-7)</b> will be supported by this educational program.</li> <li>• Applications will be reviewed by a scientific review committee (<b>SRC</b>).</li> <li>• The amount of the award will depend upon SRC’s evaluation of proposal and costs involved and will be stated clearly in the award agreement.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |



|                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Key Dates:</b> | <ul style="list-style-type: none"> <li>• RFP release date: <b>April 22, 2026.</b></li> <li>• Grant Application due <b>June 23, 2026.</b> Please note the deadline is 23:59 Eastern Time (New York, GMT -5). Applications submitted after deadline will not be reviewed.</li> <li>• Review of applications by SRC: <b>July-August 2026</b></li> <li>• Anticipated Grant Award Notification Date: <b>Sept-Oct 2026</b><br/>Grants will be distributed following a fully executed agreement.</li> <li>• Anticipated Project Start and End Dates: <b>November 1, 2026, to May 1, 2027.</b></li> </ul> |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>How to Apply:</b> | <p>Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.</p> <ul style="list-style-type: none"> <li>• Please go to <a href="https://www.cybergrants.com/pfizer/knowledge">https://www.cybergrants.com/pfizer/knowledge</a> and sign in. First-time users should click "Create your password". <i>[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]</i></li> <li>• <b>In the application:</b> <ul style="list-style-type: none"> <li>• Under Program Overview, for the question "What type of request are you submitting?" select "Support for a Visiting Professorship."</li> <li>• For the question, "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes.</li> <li>• Select the following Competitive Grant Program Name: 2026 ONC US PCF Visiting Professorship</li> <li>• Select the following Primary Area of Interest: <b>Oncology – Genitourinary</b>; Select <b>Genitourinary – Prostate</b> for the Cancer Type Detail question.</li> </ul> </li> <li>• Requirements for submission: <ul style="list-style-type: none"> <li>• Complete all required sections of the online application and upload your project proposal in the Proposal/Protocol field.</li> <li>• See Appendix for more details of submission requirements.</li> </ul> </li> <li>• If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.</li> <li>• Please click <a href="#">here</a> for a checklist to refer to PRIOR to submitting your application.</li> </ul> <p><b>IMPORTANT:</b> Applications submitted after the due date will not be reviewed.</p> |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                   |                                                                                                                                                                                                                                                                                          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Questions:</b> | <p>If you have questions regarding this RFP, please email Ari Karon (<a href="mailto:akaron@pcf.org">akaron@pcf.org</a>) and Lori Carpenter (<a href="mailto:lori.carpenter@pfizer.com">lori.carpenter@pfizer.com</a>) with the subject line: 2026 ONC US PCF Visiting Professorship</p> |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|



|                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Grant Agreements:</b></p>                               | <ul style="list-style-type: none"> <li>• If your Grant application is approved, your Institution will be required to enter into a written grant agreement with Pfizer. Please click <a href="#">here</a> to view the core terms of the agreement.</li> <li>• Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.</li> <li>• Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.</li> <li>• Except where prohibited by applicable local laws or regulations and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization in its country of domicile.</li> <li>• This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.</li> </ul> |
| <p><b>Review and Approval Process:</b></p>                    | <ul style="list-style-type: none"> <li>• Grant requests received in response to a specific RFP are reviewed by a scientific review committee (SRC) to make final grant decisions.</li> <li>• The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <p><b>Mechanism by which Applicants will be Notified:</b></p> | <ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above.</li> <li>• Applicants may be asked for additional clarification during the review period.</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Appendix

### RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins and should include all the information requested in Section III Requirements (above). Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

#### Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project in terms of learning and expected outcomes.

### **Needs Assessment for the Project**

- Describe your organization's needs assessment for this proposed project, which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives).

### **Project Design and Methods**

- Describe the planned project, the approach, and the way the planned methods could address the established need.

### **Innovation**

- Explain what measures you have taken to ensure that this project is original and does not duplicate other projects or materials already developed by your organization. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed by your organization, if applicable.

### **Evaluation and Outcomes**

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Specify at least two quantifiable Program outcomes you plan to track and report for your organization at 6 and 12 months. Identify the data sources your organization expects to use to assess these outcomes and how data will be collected and analyzed. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Also specify the amount of change expected from this project in terms of the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

### **Participation in PCF Scientific Retreat**

- We will provide travel and registration support for one participant per awarded organization to attend the 2027 PCF Scientific Retreat, an invitation-only meeting that is the foremost scientific conference in the world on the biology and treatment of prostate cancer. The Retreat is held annually in autumn (October). Please indicate interest and willingness to attend.

### **Participation in Video Interviews**

- After the program, we will create videos in which participants describe their baseline testing challenges, learnings, practice-specific solutions, and concrete outcomes. These videos will be hosted publicly on UroToday. Please indicate your interest and willingness to participate.

### **Anticipated Project Timeline**

- Provide an anticipated timeline for your project, including project start/end dates.

### **Additional Information**

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

### **Organization Detail**

- Describe the attributes of the organization / associations that will support and facilitate the execution of the program and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.



## Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget, please keep the following items in mind:
  - Independent Medical Education Grants and Visiting Professorships awarded by GMG **cannot** be used to purchase therapeutic assets (prescription or non-prescription).
  - **Pfizer may support up to 28% of overhead costs associated with the total proposed project budget. Please [click here](#) for details.** To be considered for support, general organizational running (i.e., overhead) costs such as legal fees, insurance, heating and lighting etc. should be included in an Institutional Overhead (if required). Most overhead/running costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, overhead/running costs that are specific to the project or study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.